270 related articles for article (PubMed ID: 32452732)
1. Adverse Events to the Gadolinium-based Contrast Agent Gadoxetic Acid: Systematic Review and Meta-Analysis.
Schieda N; van der Pol CB; Walker D; Tsampalieros AK; Maralani PJ; Woo S; Davenport MS
Radiology; 2020 Dec; 297(3):565-572. PubMed ID: 32452732
[TBL] [Abstract][Full Text] [Related]
2. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
Woolen SA; Shankar PR; Gagnier JJ; MacEachern MP; Singer L; Davenport MS
JAMA Intern Med; 2020 Feb; 180(2):223-230. PubMed ID: 31816007
[TBL] [Abstract][Full Text] [Related]
3. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment.
Gauthier ID; Macleod CA; Sathiadoss P; McGrath TA; Nair V; Schieda N
Abdom Radiol (NY); 2022 Mar; 47(3):1196-1201. PubMed ID: 34997298
[TBL] [Abstract][Full Text] [Related]
4. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid.
Starekova J; Bruce RJ; Sadowski EA; Reeder SB
Radiology; 2020 Dec; 297(3):556-562. PubMed ID: 32990511
[TBL] [Abstract][Full Text] [Related]
5. Adverse Events Associated with Intra-Arterial Administration of Gadolinium-Based Contrast Agents: A Systematic Review and Meta-Analysis.
MacLeod CA; Gauthier I; Davenport MS; McGrath TA; Khan F; Dos Santos MP; McInnes MDF; Schieda N
J Vasc Interv Radiol; 2023 Apr; 34(4):568-577.e10. PubMed ID: 36464013
[TBL] [Abstract][Full Text] [Related]
6. Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.
Tseng TY; Tseng JH; Huang BS; Lin SY; Chen CB; Fang YW; Lin G; Lai YC
Abdom Radiol (NY); 2021 Aug; 46(8):3995-4001. PubMed ID: 33742216
[TBL] [Abstract][Full Text] [Related]
7. Breakthrough Hypersensitivity Reactions to Gadolinium-based Contrast Agents and Strategies to Decrease Subsequent Reaction Rates: A Systematic Review and Meta-Analysis.
Walker DT; Davenport MS; McGrath TA; McInnes MDF; Shankar T; Schieda N
Radiology; 2020 Aug; 296(2):312-321. PubMed ID: 32427558
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases.
Tsushima Y; Kanal E; Thomsen HS
Br J Radiol; 2010 Jul; 83(991):590-5. PubMed ID: 20413447
[TBL] [Abstract][Full Text] [Related]
9. Nephrogenic systemic fibrosis is found only among gadolinium-exposed patients with renal insufficiency: a case-control study from Denmark.
Elmholdt TR; Pedersen M; Jørgensen B; Søndergaard K; Jensen JD; Ramsing M; Olesen AB
Br J Dermatol; 2011 Oct; 165(4):828-36. PubMed ID: 21692765
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium-based contrast agents: What we learned from acute adverse events, nephrogenic systemic fibrosis and brain retention.
Bäuerle T; Saake M; Uder M
Rofo; 2021 Sep; 193(9):1010-1018. PubMed ID: 33348385
[TBL] [Abstract][Full Text] [Related]
11. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
12. Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
Alfano G; Fontana F; Ferrari A; Solazzo A; Perrone R; Giaroni F; Torricelli P; Cappelli G
Magn Reson Imaging; 2020 Jul; 70():1-4. PubMed ID: 32112811
[TBL] [Abstract][Full Text] [Related]
13. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
14. Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients.
Abujudeh HH; Kaewlai R; Kagan A; Chibnik LB; Nazarian RM; High WA; Kay J
Radiology; 2009 Oct; 253(1):81-9. PubMed ID: 19709997
[TBL] [Abstract][Full Text] [Related]
15. Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.
Edwards BJ; Laumann AE; Nardone B; Miller FH; Restaino J; Raisch DW; McKoy JM; Hammel JA; Bhatt K; Bauer K; Samaras AT; Fisher MJ; Bull C; Saddleton E; Belknap SM; Thomsen HS; Kanal E; Cowper SE; Abu Alfa AK; West DP
Br J Radiol; 2014 Oct; 87(1042):20140307. PubMed ID: 25230161
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
17. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis.
Agarwal R; Brunelli SM; Williams K; Mitchell MD; Feldman HI; Umscheid CA
Nephrol Dial Transplant; 2009 Mar; 24(3):856-63. PubMed ID: 18952698
[TBL] [Abstract][Full Text] [Related]
18. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy: a primer for radiologists.
Prasad SR; Jagirdar J
J Comput Assist Tomogr; 2008; 32(1):1-3. PubMed ID: 18303280
[TBL] [Abstract][Full Text] [Related]
19. Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
Semelka RC; Prybylski JP; Ramalho M
Magn Reson Imaging; 2019 May; 58():174-178. PubMed ID: 30471330
[TBL] [Abstract][Full Text] [Related]
20. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
